BEIJING and BRIDGEWATER, N.J., April 9, 2026 /PRNewswire/ — Gan & Lee Pharmaceuticals (hereinafter referred to as “Gan & Lee”, SSE: 603087) announced the signing of an exclusive licensing agreement with JW Pharmaceutical, a leading pharmaceutical company in South Korea. Under the agreement, the two parties will collaborate on the clinical development, regulatory filing, and commercialization in South Korea of Bofanglutide Injection, a bi-weekly (once every two weeks) Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) independently discovered and developed by Gan & Lee.

Strategic Alliance: By Leveraging JW’s Strengths in R&D and Commercialization in South Korea, Gan & Lee Will Establish a Strong Commercial Footprint in South Korea’s High-Potential Metabolic Disease Market 

Under the terms of the agreement, JW Pharmaceutical will be granted the exclusive rights to develop and commercialize Bofanglutide Injection in South Korea. Gan & Lee Pharmaceuticals will receive a one-time, non-refundable upfront payment of USD 5 million. Additionally, Gan & Lee is eligible to receive milestone payments totaling USD 76.1 million, contingent upon research and development progress, regulatory approvals, and commercialization achievements. Following the product’s commercial launch, Gan & Lee will also receive tiered royalties based on net sales. The total potential transaction value reaches up to USD 81.1 million (excluding royalties).

This collaboration marks the third overseas out-licensing deal for Gan & Lee’s Bofanglutide Injection, following previous partnerships in Latin America and India. According to data from Grand View Research, the GLP-1RA market in the Asia-Pacific region reached USD 5.47 billion in 2025 and is projected to grow to USD 16.95 billion by 2033, representing a compound annual growth rate (CAGR) of 14% ^[1], making it one of the fastest-growing regions globally. Currently, the treatment penetration rate of GLP-1 drugs remains extremely low, indicating massive growth potential. As a mature market in the Asia-Pacific region, South Korea’s GLP-1RA market size reached USD 526 million in 2025 and is expected to increase to USD 1.6 billion by 2033 ^[2]. With its high acceptance of innovative drugs and strong patient purchasing power, the South Korean market has become a strategic foothold for multinational pharmaceutical companies entering East Asia. This collaboration marks another key step in the rapid global expansion of Gan & Lee’s differentiated bi–weekly GLP–1RA, Bofanglutide.

Steady Progress in Global Phase III Clinical Trials; Bi-weekly Dosing Regimen Significantly Enhances Patient Compliance

Currently, as the world’s first bi-weekly GLP-1RA to enter Phase III clinical research, Bofanglutide has advanced into the critical Phase III stage of its global development for three proposed indications: obesity/overweight, type 2 diabetes mellitus (T2DM), and obstructive sleep apnea (OSA). Existing clinical data demonstrate that Bofanglutide can effectively reduce body weight and blood glucose levels while comprehensively improving other metabolic parameters, yielding overall metabolic benefits. Its safety and tolerability profiles are consistent with other GLP-1RA class therapies. The bi-weekly dosing regimen further reduces the annual number of injections by 50% compared to mainstream once-weekly GLP-1RAs. This is anticipated to substantially boost patient adherence, offering a more convenient treatment option for the long-term, effective management of metabolic diseases.

As the global burden of metabolic diseases continues to rise, GLP-1 therapies are encountering tremendous market opportunities. South Korea, as one of the world’s key pharmaceutical markets, exhibits a robust demand for innovative diabetes  and weight-loss therapies. This collaboration will effectively address the clinical and commercial needs of the South Korean market for highly efficacious and convenient treatment regimens.

“This partnership with JW Pharmaceutical marks another pivotal step in the globalization strategy for Bofanglutide,” stated Dr. Zhi Li, Chief Business  Officer of Gan & Lee Pharmaceuticals. “GLP-1 therapies are reshaping the global treatment landscape for metabolic diseases. The convenience of Bofanglutide’s bi-weekly dosing and its compelling clinical benefits will help address the unmet medical needs of South Korean patients. With over 80 years of experience, JW brings deep development and commercial expertise in metabolic diseases—a key factor in our decision to partner with JW.”

Young-sub Shin, CEO of JW Pharmaceutical, commented: “This agreement represents a significant milestone in expanding our product portfolio within the rapidly growing therapeutic area of metabolic diseases, particularly diabetes and obesity. JW Pharmaceutical will leverage its established expertise in clinical development and regulatory execution, remaining committed to advancing the development and commercialization of Gan & Lee’s Bofanglutide in South Korea, thereby bringing innovative treatment options to South Korean patients.”

About Bofanglutide

Bofanglutide Injection (GZR18), independently developed by Gan & Lee Pharmaceuticals, is a bi-weekly administered GLP-1RA designed for the treatment of obesity/overweight, type 2 diabetes mellitus (T2DM), and other metabolic diseases. Clinical research data indicates that Bofanglutide can effectively reduce body weight and lower blood glucose levels, while comprehensively improving other metabolic parameters. With safety and tolerability profiles consistent with the GLP-1RA class of drugs, it is poised to potentially become the world’s first commercially available bi-weekly GLP-1RA. Currently, the global development of Bofanglutide Injection has entered the Phase III clinical research stage.

About JW Pharmaceutical

Founded in 1945, JW Pharmaceutical Corporation has been a leader in Korea’s therapeutic pharmaceutical market, guided by its founding principles of respect for life and a spirit of challenge. With a robust portfolio of original medicines, JW Pharmaceutical has focused on innovative drug discovery and development since the establishment of its Central Research Institute in 1983 and the C&C Research Laboratories in 1992. Through advanced research technologies, including its AI-based drug discovery and development platform, JWave, the company has built a strong pipeline in areas such as oncology, immunology, and regenerative medicine. JW Pharmaceutical also actively pursues diverse research initiatives aligned with global trends through open innovation. JW Pharmaceutical Corporation is listed on the Korea Exchange under the ticker “001060.”

References:

1. Grand View Research. (2026). Asia Pacific GLP-1 Receptor Agonist Market Size & Outlook, 2033 (Horizon Databook), https://www.grandviewresearch.com/horizon/outlook/glp-1-receptor-agonist-market/asia-pacific
2. Grand View Research. (2026). South Korea GLP-1 Receptor Agonist Market Size & Outlook, 2033, https://www.grandviewresearch.com/horizon/outlook/glp-1-receptor-agonist-market/south-korea
3. Gan & Lee Pharmaceuticals Officially Initiates GRADUAL-3, China’s First Phase III Clinical Trial for Weight Management with a Once-Monthly GLP-1RA. [Press Release], https://mp.weixin.qq.com/s/wHWm0CPGRfwTK6iTcjHwfA
4. From “Follower” to “Leader”: Domestic Bi-weekly Bofanglutide Debuts at ADA, Ushering in “China Time” for Diabetes Treatment. [Press Release], https://mp.weixin.qq.com/s/6p_ou6d4DmopTennpKxbCg
5. Gan & Lee Pharmaceuticals’ Bofanglutide (GZR18) Injection Approved for Clinical Trial of New Indication: Moderate to Severe Obstructive Sleep Apnea in Obese Adult Patients. [Press Release], https://mp.weixin.qq.com/s/AT_v7pctR5CxaX7BgHcN5A
6. Gan & Lee Pharmaceuticals Enters into an Exclusive Commercial Agreement with Renowned Latin American Pharmaceutical Company PC for Bofanglutide. [Press Release], https://mp.weixin.qq.com/s/lTMxrLIb6ppZ76O9o5pGMw
7. Gan & Lee Pharmaceuticals Enters into a Partnership with Leading Indian Pharmaceutical Company Lupin. [Press Release], https://mp.weixin.qq.com/s/w44yByJ68buuyXSxwItFhg

About Gan & Lee

Gan & Lee Pharmaceuticals is a high-tech biopharmaceutical company and the first in China to master industrial-scale manufacturing technologies for recombinant insulin analogs. The Company has established a comprehensive insulin research and development pipeline.

Currently, Gan & Lee offers six core insulin products, including five insulin analogs: insulin glargine injection (Basalin^®; EU brand name Ondibta^®), insulin lispro injection (Prandilin^®; EU brand name: Bysumlog^®), insulin aspart injection (Rapilin^®; EU brand name: Dazparda^®), premixed insulin lispro protamine suspension injection (25R) (Prandilin^®25), and insulin aspart 30 injection (Rapilin^®30); as well as one human insulin product, premixed human insulin protamine suspension injection (30R) (Similin^®30), together with related delivery devices. These products cover the long-acting, rapid-acting, and premixed insulins.

In China’s second round of national volume-based procurement for insulin, Gan & Lee ranked first among selected companies by contracted volume for insulin analogs, further strengthening its domestic market position. In parallel, the Company continues to advance its international expansion. Insulin glargine injection has received marketing authorization from the European Commission (EC), while for insulin lispro injection and insulin aspart injection, it has received the positive opinion from CHMP of EMA. Gan & Lee is steadily progressing toward its goal of becoming a key global participant in the field of metabolic diseases.

Looking forward, Gan & Lee is committed to achieving comprehensive coverage across the diabetes treatment landscape and further enhancing its competitive position in this therapeutic area. The Company will also actively pursue the development of innovative chemical drugs and biologics, with a strategic focus on metabolic diseases, cardiovascular diseases, and other therapeutic areas.

NYSE issues a pre-market daily advisory direct from the trading floor.

NEW YORK, April 9, 2026 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

Kristen Scholer delivers the pre-market update on April 9th

• ICE Brent Crude oil resumes its gain Thursday morning after falling below $95 a barrel Wednesday on the two-week ceasefire between the U.S. and Iran.
• Shares of Meta Platforms, a top NYSX holding, are set to add to yesterday’s 6.5% rally after its ‘Muse Spark’ AI model release.
• The fourth annual NYSE Sustainability Leaders Summit takes place this afternoon, convening executives at 11 Wall Street.

Opening Bell
Oliver Wyman Forum (NYSE: MRSH) rings the NYSE Opening Bell

Closing Bell
MNTN (NYSE: MNTN) rings the NYSE Closing Bell

For market insights, IPO activity, and today’s opening bell, download the NYSE TV App: TV.NYSE.com

Delivering technical clarity, financial calculus, and courtroom credibility in AI-related litigation.

NEW YORK, April 9, 2026 /PRNewswire/ — J.S. Held announced today the expansion of its integrated capabilities to support clients addressing the legal, technical, and financial complexities of artificial intelligence (AI)-related disputes. This expansion comes as the firm’s Q1 AI Disputes Monitor projects a 50% rise in AI-related case filings, underscoring the growing need for specialized expertise in this fast-evolving and complex area of litigation. 

AI disputes center on the development, deployment, or impact of artificial intelligence and differ fundamentally from traditional litigation. These matters involve systems that are simultaneously technical artifacts, economic assets, and evidentiary tools, each dimension influencing the others. Unlike conventional matters where questions can be addressed in isolation, AI disputes require a unified multidisciplinary approach. J.S. Held connects technical insight, financial analysis, and litigation experience to provide comprehensive support across all phases of dispute resolution.

Why AI Disputes Demand Integrated Expertise

J.S. Held offers integrated expertise to address the unique challenges of AI-related litigation. This approach is essential due to the complex, interdependent nature of AI systems. These matters often require:

• Technical clarity to explain how AI systems behave, including digital forensics, model versioning, and data provenance.
• Financial calculus to quantify economic damages, assess market impact, and evaluate intellectual property value.
• Courtroom credibility to present findings in a manner that withstands legal scrutiny across jurisdictions.

“AI disputes uniquely require integrated expertise because AI systems exist at the intersection of three inseparable domains,” said JP Brennan, Senior Managing Director at J.S. Held. “Our work focuses on helping clients understand and explain how these systems operate in real-world contexts. We apply structured forensic methods—such as system log reconstruction, prompt replay, and model version analysis—to support investigations and testimony.”

J.S. Held experts are known for a “teaching, not telling” approach to expert testimony. Rather than simply offering an opinion, they break down complex information into clear, logical explanations that judges and juries can easily follow. “AI-related disputes increasingly require a combination of financial expertise, technical understanding, and legal analysis that is clearly communicated and able to withstand courtroom scrutiny,” said James E. Malackowski, CPA, CLP, Chief Intellectual Property Officer at J.S. Held and Senior Managing Director at Ocean Tomo. “We provide economic damages assessments, intellectual property valuation, and market impact analysis that help judges and juries evaluate questions of fair use, licensing, and commercial harm.”

Experience with AI Systems Across Sectors

J.S. Held’s work with AI systems spans multiple industries and use cases. Recent engagements include: 

• AI Risk and Governance: Designed and implemented an AI risk and controls framework for a property and casualty insurer, improving transparency, regulatory readiness, and model oversight.
• Vendor Ecosystem Advisory: Conducted vendor benchmarking and risk assessments for third-party AI tools at a fintech company, reducing costs, improving governance, and mitigating vendor lock-in.
• Model Validation: Independently assessed a machine-learning fraud detection model for a digital payments platform, identifying performance and bias risks and delivering recommendations to strengthen reliability and compliance.

These engagements reflect J.S. Held’s ability to scale technical insight and support clients managing the operational and regulatory implications of AI adoption and related litigation risk.

AI Copyright Litigation – Thomson Reuters v. Ross Intelligence

J.S. Held’s role in Thomson Reuters Enterprise Centre GmbH and West Publishing Corp. v. Ross Intelligence Inc. (U.S. District Court, D. Delaware, Case No. 1:20-cv-613-SB) demonstrates the firm’s ability to support litigation at the intersection of AI and intellectual property.

James E. Malackowski was engaged as a financial damages expert to assess the fourth fair use factor (market impact) in this matter involving the use of proprietary legal research content to train a generative AI system. The engagement addressed questions of licensing markets for training data, economic substitution, and the valuation of editorial content in AI development.

Executive Perspective – Scaling with Purpose

“As AI technologies continue to evolve, our clients face increasingly complex disputes that demand more than traditional expertise,” said Lee Spirer, Chief Executive Officer of J.S. Held. “We are laser-focused on building highly integrated teams that combine technical, financial, and legal insight. This approach enables us to support both in-house and outside counsel with the depth, precision, and coordination required to address the evolving demands of AI-related litigation.”

J.S. Held’s investment in cross-disciplinary capabilities reflects its long-term commitment to delivering scalable, high-impact solutions in areas where the stakes are greatest.

J.S. Held AI Disputes Monitor – Q1 2026 Update

The Q1 2026 update of the J.S. Held AI Disputes Monitor reveals a sharp rise in litigation, particularly in the insurance sector.  Multiple lawsuits filed across the United States in early 2026 indicate growing scrutiny of AI-driven decision-making in claims processing and policy coverage, particularly within property and casualty insurance.

A total of 31 AI-related lawsuits were filed in Q1, marking a 46% increase over the average quarterly rate in 2025. At this pace, 2026 is projected to exceed the previous year’s total by nearly 50 percent.

The first-quarter 2026 snapshot underscores the accelerating pace of AI-related disputes and the growing demand for expert insight into the technical, financial, and legal dimensions of algorithmic decision-making.

To explore the full set of findings, download the latest edition of the J.S. Held AI Disputes Monitor.

About J.S. Held

J.S. Held is a global consulting firm that combines technical, scientific, financial, and strategic expertise to advise clients seeking to realize value and mitigate risk. Our professionals serve as trusted advisors to organizations facing high stakes matters demanding urgent attention, staunch integrity, proven experience, clear-cut analysis, and an understanding of both tangible and intangible assets. The firm provides a comprehensive suite of services, products, and data that enable clients to navigate complex, contentious, and often catastrophic situations.

More than 1,500 professionals serve organizations across six continents, including 84% of the Global 200 Law Firms, 75% of the Forbes Top 20 Insurance Companies (90% of the NAIC Top 50 Property & Casualty Insurers), and 71% of Fortune 100 Companies.

J.S. Held, its affiliates and subsidiaries are not certified public accounting firm(s) and do not provide audit, attest, or any other public accounting services. J.S. Held is not a law firm and does not provide legal advice.  Securities offered through PM Securities, LLC, d/b/a Phoenix IB or Ocean Tomo Investments, a part of J.S. Held, member FINRA/SIPC.  All rights reserved.

Contact:

Kristi L. Stathis | Global Public Relations | +1 786 833 4864 | Kristi.Stathis@jsheld.com 

Accomplished medical research leader will oversee NCCN programs to advance clinical trials and improve the quality, effectiveness, and accessibility of cancer care.

PLYMOUTH MEETING, Pa., April 9, 2026 /PRNewswire/ — Today, the National Comprehensive Cancer Network^® (NCCN^®)—an alliance of leading cancer centers devoted to patient care, research, and education—announced the selection of Nancy L. Lewis, MD, MBS, FACP, as new Chief Scientific Officer (CSO).

Nancy L. Lewis, MD, MBS, FACP, Named New Chief Scientific Officer for National Comprehensive Cancer Network (NCCN). Learn more at NCCN.org.

Dr. Lewis is an experienced biomedical researcher with expertise in clinical trials for treating solid tumors and hematologic malignancies. She most recently served as Senior Clinical Program Leader for Novartis Pharmaceuticals, after several years as an Associate Professor for various prestigious academic cancer centers. She holds degrees from Penn State University, Temple University School of Medicine, and Rutgers University. Dr. Lewis completed residency at the University of Rochester and Fellowship at Fox Chase Cancer Center—one of NCCN’s founding Member Institutions.

“This is a pivotal time for cancer research; there are many successes to build on yet so much still to do. Dr. Lewis is the perfect person to oversee the work we do to foster innovation and knowledge discovery that improves the lives of people with cancer,” said Crystal S. Denlinger, MD, CEO, NCCN. “She will be an important asset to our leadership team as she helps us ensure our research and clinical programs continue to advance outcomes in oncology around the world.”

Dr. Lewis has previously been honored with awards from some of the foremost cancer organizations across the country, including the American Association for Cancer Research (AACR), The American Society of Clinical Oncology (ASCO), and the American Cancer Society (ACS).

As CSO, Dr. Lewis will assist in the NCCN Oncology Research Program (ORP) as well as key aspects of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) and NCCN Guidelines for Patients^®. She will have oversight of the NCCN Biomarkers Compendium^®; NCCN Radiation Therapy Compendium™, and NCCN Imaging Appropriate Use Criteria™. Dr. Lewis will also assist with NCCN’s Continuing Medical Education Program and with relevant global and policy initiatives.

“I am thrilled to join the National Comprehensive Cancer Network and contribute to its extraordinary legacy of advancing high‑quality cancer care,” said Dr. Lewis. “I look forward to working with NCCN’s exceptional collaborators to tackle emerging challenges and drive innovative solutions that improve the lives of patients everywhere.”

Dr. Lewis will succeed Dr. Denlinger who previously held the position of CSO before becoming CEO for the organization. Dr. Lewis will assume her new role in May 2026.  

About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network^® (NCCN^®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) provide transparent, evidence-based, expert consensus-driven recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients^® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation^®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information.

Media Contact:
Rachel Darwin
267-622-6624
darwin@nccn.org

The multi-year collaboration aims to scale molecular data storage infrastructure and unlock breakthrough cost efficiencies by 2030.

PISCATAWAY, N.J. and LOS ANGELES, April 9, 2026 /PRNewswire/ — GenScript Biotech Corporation, the world’s leading provider of CMOS-based DNA synthesis technologies, and Mimulus Corp, the pioneer in Molecular Archive Technology™, today announced a strategic collaboration to industrialize DNA-based data storage, a technology poised to transform how the world preserves data in the age of Artificial Intelligence.

As the AI-driven surge in global data creation accelerates exponentially, existing archival storage systems built on magnetic tape and hard drives are reaching their economic and environmental limits. The strategic partnership between GenScript and Mimulus aims to address this challenge by architecting the world’s first molecular archival storage that requires no electricity to preserve data once encoded into DNA and can store massive volumes of information for centuries.

Under the agreement, GenScript will industrialize high‑throughput DNA synthesis at scale, targeting a leap from millions to billions of oligonucleotides synthesized in parallel on a single chip. Building on its highly-validated manufacturing platform, currently capable of synthesizing 8 million oligonucleotides in parallel on a single chip, GenScript will deliver the scale, reproducibility, and validation required to make emerging applications like molecular data storage commercially viable. While the DNA technology landscape remains fragmented across writing, reading, and storage, GenScript brings capabilities across key parts of the DNA data storage value chain, including synthesis, sequencing-related technologies, and platform development. Combined with Mimulus’ proprietary Molecular Archive Technology™, this capability enables molecular data storage to transition from laboratory innovation to commercially scalable infrastructure.

“When a new category emerges, the winners are built on infrastructure,” said Sherry Shao, Rotating CEO of GenScript Biotech Corporation. “At GenScript, we believe in Scripting Possibilities – turning what was once theoretical into scalable reality. DNA-based data storage will only become a viable real-world infrastructure when synthesis can be delivered at extraordinary throughput, quality, and cost. We are building that industrial foundation to transform molecular storage from being ‘scientific promise’ into ‘global reality’.”

Mimulus Glacier Data Storage Card is replacing decaying magnetic infrastructure. By combining GenScript’s proven industrial-scale synthesis engine with Mimulus’s molecular transcoding architecture, this credit-card-sized device creates a completely off-stack and off-grid physical vault. The collaboration seeks to dramatically accelerate the cost curve of DNA-based storage and unlock economically viable archival systems for global cloud and AI workloads.

“Trying to solve a pressing 21st-century AI data problem with mid-century magnetic tape is a bit like trying to launch a rocket with a steam engine,” said Todd R. Nelson, Ph.D., Founder and Chairman of Mimulus Corp. “But this isn’t just about building a better storage device; it’s about liquidating an operational liability to fuel the AI revolution. By combining our proprietary architecture with GenScript’s unparalleled manufacturing scale, we are printing power permits. We are handing hyperscalers the exact megawatts they need to turn on their AI supercomputers today, unlocking a trillion-dollar flywheel that reshapes the economics of the cloud.”

About GenScript Biotech Corporation

Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop ground breaking treatments and products. As a cornerstone of the global life science ecosystem, GenScript actively collaborates with a diverse network of partners—from academic institutions to industry leaders—to co-create cutting-edge solutions that redefine service excellence. Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript has become a trusted global partner with a team of 6,100+ employees, supporting over 200,000 customers across 100+ countries and regions, including the world’s Top 20 pharma companies. For more information: www.genscript.com

About Mimulus Corp

Mimulus Corp is a venture-backed biotechnology company architecting the world’s first economically sustainable and physically permanent archival infrastructure for the age of AI. By combining the scaling laws of the semiconductor industry with the density of synthetic biology, Mimulus solves the global archival storage crisis and liberates critical grid power for AI compute. Led by a team of serial entrepreneurs with over $7 billion in capital formation experience, Mimulus is making the future molecular. For more information: www.mimulus.co

Media Contacts:

For GenScript: Melis Inceer, Head of Integrated Communications & Content, melis.inceer@genscript.com

For Mimulus Corp: Colette Patnaude, Founder, press@mimulus.co

Partnership brings adaptive AI upskilling to Georgia’s top-ranked economic development community, targeting the region’s advanced manufacturing and industrial workforce

NEWPORT BEACH, Calif. and LAGRANGE, Ga., April 9, 2026 /PRNewswire/ — MindHYVE.ai™, Inc. and the Development Authority of LaGrange have signed a Strategic Collaboration Framework (SCF) to deploy AI-powered adaptive learning across LaGrange’s workforce ecosystem. The partnership will introduce ArthurAI™, MindHYVE’s agentic vocational learning platform, to address upskilling demands in one of the Southeast’s largest manufacturing and industrial corridors.

MindHYVE.ai™ and the Development Authority of LaGrange announce a Strategic Collaboration Framework to deploy AI-powered adaptive workforce training across Georgia’s largest business park ecosystem.

LaGrange currently ranks as the top economic development community in Georgia, and sixth nationally for micropolitans, according to Site Selection Magazine. The region’s Georgia International Business Park (GIBP), the largest in the Southeast and fourth largest in the country, is home to more than 41 international companies across 18 countries, anchored by multiple Fortune 500 companies, including Kia and its supplier network. With a regional workforce of approximately 250,000 and over 50,000 manufacturing jobs, employers have identified a growing gap between effective training and upskilling programs and the basic technical skills required by employers in the region.

Under the framework, MindHYVE.ai™ will work with the Development Authority to deploy ArthurAI™ across employer-driven training programs, beginning with multiple pilot cohorts in the region’s advanced manufacturing and automotive supplier networks. The collaboration includes:

• ArthurAI™ Vocational Learning Edition (VLE) — adaptive upskilling aligned to employer-identified competencies; adjusts to each worker’s learning pace, background, and role in real time, whether they’re a first-time floor operator or a seasoned technician learning a new system
• ArthurAI™ Corporate Learning Edition (CLE) — AI-fluency training for supervisors, management, and corporate teams, delivered in partnership with the California Institute of Artificial Intelligence (CIAI)
• The Dawn Directive™ — the California Institute of Artificial Intelligence’s (CIAI) AI literacy and fluency program, powered by MindHYVE.ai™; a 4-month, 18-course, 360-hour AI fluency certification designed for regulated industries and the industrial workforce

Making ArthurAI™ Cost-Neutral for Georgia Employers

A critical accelerator in the LaGrange deployment is Georgia’s robust workforce funding ecosystem. ArthurAI™ training programs are designed to qualify for stacked funding through WIOA Title I (Workforce Innovation and Opportunity Act), the Georgia Work Ready credential framework, federal manufacturing training grants administered through the Department of Labor, and Economic Development partnership opportunities through the Technical College System of Georgia. For participating employers, this funding architecture has the potential to make ArthurAI™ deployment significantly more accessible. The Development Authority of LaGrange will serve as the funding coordination gateway for GIBP employers entering the program.

Initial deployment will focus on parallel pilot programs with local advanced manufacturing and automotive suppliers, comparing adaptive AI-driven training against traditional methods across metrics including completion time, competency retention, and employer satisfaction. The partnership also establishes a pathway for phased expansion across LaGrange’s diversified industrial base, with the Development Authority serving as the deployment gateway for ArthurAI™ across GIBP’s full 100+ company ecosystem.

“Workforce development has to meet people where they are, not where a standard curriculum assumes they should be,” said Bill Faruki, Founder and CEO of MindHYVE.ai™. “ArthurAI™ adapts to each learner’s background and pace, whether they’re a first-time manufacturing worker or a seasoned operator learning a new system. LaGrange’s employer base and economic development leadership make it an ideal environment to demonstrate what that looks like at scale.”

“I built ArthurAI™ on one non-negotiable principle: AI should make workers more valuable, not more vulnerable,” Faruki added. “We don’t deploy technology that displaces people — we deploy technology that makes them indispensable. If it doesn’t grow employment, we don’t ship it. LaGrange will be the proof point.”

“The Development Authority of LaGrange is committed to ensuring our workforce keeps pace with the industries that drive our economy,” said Scott Malone, President of the Development Authority of LaGrange. “This collaboration gives us a new tool to deliver training that’s faster, more personalized, and directly aligned to what our employers need.”

“We are a community built for industry, powered by talent and proven by results. We are excited to be positioned to continue leading the State of Georgia in deployment of new training technologies in ethical AI,” said Kelley Bush, Director of Workforce Development and Existing Industry for the Development Authority of LaGrange.

About the Development Authority of LaGrange

The Development Authority of LaGrange drives economic growth and business investment in LaGrange, Georgia and Troup County. Home to the Georgia International Business Park — the largest in the Southeast — LaGrange supports over 100 manufacturers, 41 international companies across 18 countries, and a regional workforce of approximately 250,000. The Authority provides strategic oversight, site selection, workforce training coordination, and business expansion support, and ranks as the #1 economic development community in Georgia and sixth nationally for micropolitans (Site Selection Magazine).

About the California Institute of Artificial Intelligence (CIAI)

The California Institute of Artificial Intelligence is the credentialing body behind the Dawn Directive™ — a 4-month, 18-course, 360-hour AI fluency certification framework designed to produce AI-fluent professionals across regulated industries including manufacturing, healthcare, finance, and law. The Dawn Directive™ is powered by MindHYVE.ai™’s ArthurAI™ platform and is deployed across institutional and employer partnerships in the United States and internationally.

About MindHYVE.ai™

Founded by Bill Faruki, MindHYVE.ai™ engineers domain-specific agentic AI systems for education, healthcare, law, finance, and governance. Its technology stack is powered by Eve-Fusion™, a proprietary multi-model consensus reasoning engine, and deployed on Eve-Grid™, MindHYVE’s enterprise-grade Azure-native cloud infrastructure. The company’s flagship platforms include ArthurAI™ for adaptive learning and ChironAI™ for clinical decision support, with deployments spanning North America, Asia, and Africa. MindHYVE does not use client data for model training; all training relies exclusively on synthetically generated data through Eve-Genesis™, its proprietary reasoning training framework. MindHYVE.ai™ is committed to the principle that AI adoption should grow employment, not diminish it.

For more information:
Website: www.mindhyve.ai  |  Email: hello@mindhyve.io  |  Phone: +1 (949) 200-8668

Partnership & Investment Inquiries:
James Barry  |  james.barry@mindhyve.io

Media Contact:
Marc Ortiz  |  marc.ortiz@mindhyve.io